A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (in thousands except share and per share amounts):



	Successor						Predecessor
	Year Ended December 31,			September 1 to December 31,			January 1 to August 31,			Year Ended December 31,
	2018			2017			2017			2016

Numerator:
Net (loss) income attributable to Surgery Partners, Inc.	$	(205,706	)	$	(41,316	)	$	(11,669	)	$	9,453
Less: amounts allocated to participating securities⁽¹⁾	32,426			10,481			—			—
Less: mark to redemption adjustment				15,566			—			—
Net (loss) income attributable to common stockholders	$	(238,132	)	$	(67,363	)	$	(11,669	)	$	9,453

Denominator:
Weighted average shares outstanding- basic	48,027,875			48,319,193			48,121,404			48,018,944
Effect of dilutive securities ⁽²⁾	—			—			—			171,794
Weighted average shares outstanding- diluted	48,027,875			48,319,193			48,121,404			48,190,738

(Loss) earnings per share:
Basic	$	(4.96	)	$	(1.39	)	$	(0.24	)	$	0.20
Diluted ⁽²⁾	$	(4.96	)	$	(1.39	)	$	(0.24	)	$	0.20

Securities outstanding not included in the computation of diluted (loss) earnings per share as their effect is antidilutive:
Stock options	82,602			—			—			—
Restricted shares	198,267			62,850			105,944			—
Convertible preferred stock	—			—			N/A			N/A

⁽¹⁾ Amounts allocated to participating securities includes dividends accrued during the Successor periods for the Series A Preferred Stock. The Series A Preferred Stock does not participate in undistributed losses. There were no participating securities during the Predecessor periods.

⁽²⁾The impact of potentially dilutive securities for the year ended December 31, 2018 (Successor), four months ended December 31, 2017 (Successor) and the eight months ended August 31, 2017 (Predecessor), were not considered because the effect would be anti-dilutive in each of those periods.